home / stock / immx / immx short
Short Information | Immix Biopharma Inc. (NASDAQ:IMMX)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 650,704 |
Total Actual Volume | 2,967,391 |
Short Trends | |
---|---|
Cover Days | 19 |
Short Days | 0 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 32,535 |
Average Short Percentage | 22.22% |
Is there a IMMX Short Squeeze or Breakout about to happen?
See the IMMX Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-02-2024 | $2.11 | $1.96 | $2.12 | $1.9 | 129,486 | 28,163 | 21.75% |
07-01-2024 | $1.99 | $2.12 | $2.1799 | $1.97 | 109,706 | 29,261 | 26.67% |
06-28-2024 | $2.13 | $1.98 | $2.1379 | $1.96 | 166,217 | 26,727 | 16.08% |
06-27-2024 | $2.2 | $2.13 | $2.3 | $2.12 | 162,354 | 22,323 | 13.75% |
06-26-2024 | $2.3 | $2.2 | $2.34 | $2.12 | 114,828 | 26,101 | 22.73% |
06-25-2024 | $2.3 | $2.32 | $2.46 | $2.11 | 415,918 | 55,743 | 13.4% |
06-24-2024 | $2.05 | $2.28 | $2.33 | $2.01 | 168,759 | 38,548 | 22.84% |
06-21-2024 | $1.87 | $2.04 | $2.07 | $1.87 | 159,032 | 43,929 | 27.62% |
06-20-2024 | $2 | $1.92 | $2.0445 | $1.89 | 84,904 | 18,133 | 21.36% |
06-18-2024 | $2.04 | $2.01 | $2.17 | $2 | 140,144 | 36,695 | 26.18% |
06-17-2024 | $2.05 | $2.05 | $2.25 | $2.03 | 130,852 | 37,127 | 28.37% |
06-14-2024 | $2.01 | $2.06 | $2.26 | $2.01 | 309,041 | 86,088 | 27.86% |
06-13-2024 | $2.12 | $2.08 | $2.17 | $2.011 | 60,196 | 13,322 | 22.13% |
06-12-2024 | $2.1 | $2.14 | $2.3 | $2.01 | 154,759 | 30,768 | 19.88% |
06-11-2024 | $2.07 | $2.04 | $2.08 | $2.02 | 34,268 | 2,596 | 7.58% |
06-10-2024 | $2.03 | $2.07 | $2.09 | $2 | 52,140 | 21,916 | 42.03% |
06-07-2024 | $2.01 | $2.03 | $2.15 | $2.01 | 73,189 | 15,459 | 21.12% |
06-06-2024 | $2.05 | $2.06 | $2.115 | $1.9 | 138,093 | 20,100 | 14.56% |
06-05-2024 | $1.88 | $2.08 | $2.18 | $1.8601 | 128,911 | 19,488 | 15.12% |
06-04-2024 | $2 | $1.81 | $2 | $1.7503 | 234,594 | 78,217 | 33.34% |
News, Short Squeeze, Breakout and More Instantly...
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient wi...